TITLE

Obligatory roles for follicle-stimulating hormone (FSH), estradiol and androgens in the induction of small polyfollicular ovarian cysts in hypophysectomized immature rats

AUTHOR(S)
Katryna Bogovich
PUB. DATE
April 2007
SOURCE
Endocrine (1355008X);Apr2007, Vol. 31 Issue 2, p179
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Immature hypophysectomized (HYPOXD) rats develop large, polyfollicular ovarian cysts in response to unabated, combined stimulation by subovulatory doses of human chorionic gonadotropin (hCG) and highly purified ovine follicle-stimulating hormone (FSH). Further, circulating amounts of androstenedione (A4) and estradiol (E2), but not testosterone or dihydrotestosterone (DHT), change in parallel with the development of these cysts. To determine the potential roles of either A4 or E2 at the level of the ovary in the induction of ovarian cysts, pellets containing either (1) cholesterol (placebo; controls); (2) A4; or (3) E2 were administered subcutaneously (sc) to immature HYPOXD rats. Some of these animals also received either twice-daily sc injections of 1 IU hCG, or daily sc injections of 2 μg FSH, for 13 days. Ovaries and sera were harvested from all treatment groups on the morning of day 14 of the combined-hormone treatment schedule. As expected, ovaries from HYPOXD rats treated with placebo, A4, or E2 pellets (with or without hCG) failed to display antral follicles. Ovaries from HYPOXD rats treated with FSH and a placebo pellet displayed polyfollicular, atretic, small antral follicles with unstimulated thecal shells. In addition, the ovarian stromal-interstitial tissue had an unstimulated appearance. In contrast, ovaries from HYPOXD rats treated with FSH plus either A4 or E2 implants displayed stimulated stromal-interstitial tissue as well as small follicular cysts and precysts with stimulated thecal shells. The number of cysts and precysts observed in the largest ovarian cross-sections for animals treated with FSH + A4 (17.0 ± 3.0) was less than that observed in the largest ovarian cross-sections for HYPOXD rats treated with FSH + E2 (40.2 ± 10.1; p < 0.05). To determine if the development of ovarian cysts in response to FSH + A4 was due, at least in part, to the metabolism of A4 to E2, HYPOXD rats were treated with either (1) placebo pellets; (2) pellets containing dihydrotestosterone (DHT) which cannot be metabolized to estrogen; (3) E2 pellets plus DHT pellets (E2 + DHT); (4) FSH + DHT; or (5) FSH + E2 + DHT. The largest ovarian cross-sections from FSH + DHT-treated HYPOXD rats displayed 18.3 ± 4.1 small follicles with a mean diameter of ∼0.437 mm which possessed few granulosa cells. The thecal and stromal-interstitial tissues in these ovaries were unstimulated, which indicates that these small degenerating follicles were atretic rather than cystic. In contrast, the largest ovarian cross-sections from FSH + E2 + DHT-treated HYPOXD rats displayed 51.6 ± 2.4 cysts with stimulated thecal shells and a mean diameter of ∼0.634 mm. Further, these cysts were arranged in a “string of pearls” pattern and the ovarian stromal-interstitial tissue possessed a stimulated appearance. These data demonstrate a direct, unambiguous role at the level of the ovary for unabated tonic stimulation by FSH plus estrogen in the development of small polyfollicular cysts in HYPOXD rats. Further, the data also indicate that, at least in HYPOXD rats, combined, tonic stimulation by FSH plus estrogen and androgen is sufficient for the development of small, polyfollicular ovarian cysts in a “string of pearls” pattern. These observations are in distinct contrast to our previous observations that tonic stimulation by FSH + hCG results in the induction of large ovarian cysts in HYPOXD rats and provide tantalizing new insights regarding the potential importance of specific hormones at the level of the ovary in the induction of specific types of cystic follicles.
ACCESSION #
26647598

 

Related Articles

  • HCG, hCG.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1009 

    A reference entry for the medical acronym "HCG, hCG," which means human chorionic gonadotropin, is presented.

  • Crystal structure of human chorionic gonadotropin. Lapthorn, A.J.; Harris, D.C. // Nature;6/9/1994, Vol. 369 Issue 6480, p455 

    Presents a study on the three dimensional structure of human chorionic gonadotropin (HCG). Similar topology of alpha- and beta-subunits; Receptor binding by glycoprotein hormones; Disulphide bonds; Crystallization and data collection; Formation of heterodimer; Carbohydrate structure;...

  • A clasped embrace. Patel, Dinshaw J. // Nature;6/9/1994, Vol. 369 Issue 6480, p438 

    Discusses the global folding of the human chorionic gonadotropin (hCG) placental glycoprotein hormone. Interactions between alpha- and beta-subunits; HCG as a noncovalent heterodimer; Core structure of subunit; Similar G-protein-coupled receptor of both hCG and luteinizing hormone; Central...

  • Glycoprotein hormone receptors: determinants in leucine-rich repeats responsible for ligand specificity. G. Smits; M. Campillo; C. Govaerts; V. Janssens; C. Richter; G. Vassart; L. Pardo; S. Costagliola // EMBO Journal;6/1/2003, Vol. 22 Issue 11, p2692 

    Glycoprotein hormone receptors [thyrotropin (TSHr), luteinizing hormone/chorionic gonadotropin (LH/CGr), follicle stimulating hormone (FSHr)] are rhodopsin-like G protein-coupled receptors with a large extracellular N-terminal portion responsible for hormone recognition and binding. In...

  • Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Fauser, Bart C. J. M.; Alper, Michael M.; Ledger, William; Schoolcraft, William B.; Zandvliet, Anthe; Mannaerts, Bernadette M. J. L. // Reproductive BioMedicine Online (Reproductive Healthcare Limited;Nov2010, Vol. 21 Issue 5, p593 

    A single injection of corifollitropin alfa can replace seven daily injections of recombinant FSH (rFSH) using a gonadotrophin-releasing hormone antagonist protocol in ovarian stimulation prior to IVF or intracytoplasmic sperm injection. This double-blind randomized controlled trial assessed the...

  • Recurrent Empty Follicle Syndrome. Uygur, D.; Alkan, R.N.; Batuo&gcaron;lu, S. // Journal of Assisted Reproduction & Genetics;Sep2003, Vol. 20 Issue 9, p390 

    We report a case of a recurrent empty follicle syndrome. The patient was admitted to our intracytoplasmic injection program because of her partner's azoospermia. Ovarian stimulation was accomplished using gonadotrophin therapy after treatment with oral contraceptive pills followed by...

  • A comparison between follitropin (a filled by mass and follitropin a filled by bioassay in the same egg donors. Martinez, Gustavo; Sanguineti, Fabio; Sepulveda, Jose; Dorey, Jessica; Arici, Aydin; Patrizio, Pasquale // Reproductive BioMedicine Online (Reproductive Healthcare Limited;Feb2011 Supplement, Vol. 22 Issue S1, p26 

    This study assessed the ovarian stimulation characteristics of recombinant follitropin a filled by mass (rFSH-fbm) versus recombinant follitropin et filled by conventional bioassay (rFSH-bio) in the same egg donor patients. Eleven egg donors, who had two ovarian stimulation cycles for oocyte...

  • Anti-Müllerian hormone remains highly expressed in human cumulus cells during the final stages of folliculogenesis. Grøndahl, M. L.; Nielsen, M. Eilsø; Dal Canto, M. B.; Fadini, R.; Rasmussen, I. A.; Westergaard, L. G.; Kristensen, S. G.; Andersen, C. Yding // Reproductive BioMedicine Online (Reproductive Healthcare Limited;Apr2011, Vol. 22 Issue 4, p389 

    This study evaluated whether anti-Müllerian hormone (AMH) was differentially expressed in cumulus (CC) and granulosa (GC) cells from large antral and pre-ovulatory follicles collected from individual follicles in women undergoing in-vitro maturation (IVM) or IVF treatment. Expression studies...

  • Analysis of recombinant human follicle-stimulating hormone (FSH) by mass spectrometric approaches. Grass, Josephine; Pabst, Martin; Chang, Martina; Wozny, Manfred; Altmann, Friedrich // Analytical & Bioanalytical Chemistry;Sep2011, Vol. 400 Issue 8, p2427 

    Recombinant human follicle stimulating hormone is an important drug in reproductive medicine. Thorough analysis of the heterodimeric heavily glycosylated protein is a prerequisite for the evaluation of production batches as well as for the determination of 'essential similarity' of new...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics